Program Information

• This program is designed to support innovative translational research projects that address unmet

• medical needs in Hematologic Malignancies in Australia, Canada, and Europe. 

  Areas of research may include, but are not limited to:

•  
• Health inequities and disparities in cancer care
• A broad range of adult or paediatric blood cancers
• Clinical treatment modalities (IO, cell therapy, targeted therapies etc)
• Understanding the mechanisms of patient response or resistance to treatments
• Research to improve Quality of Life (QoL) / Patient-Report Outcomes (PROs) e.g. adverse events, addressing unmet needs for patients
• Any other basic, translational and/or clinical research that addresses an unmet medical need or a gap in scientific knowledge
• Novel diagnostic, prevention, and treatment strategies
• Patient-specific factors that are predictors of toxicity
• Transformative therapeutic modalities/approaches to treatment
• Agnostic approaches to Hematologic Malignancies

Awards granted under the program may not be duplicative of funding from institutional or hospital, other governmental, non-governmental, or industry sources. Applicants seeking an award for research projects that are currently receiving or may receive partial funding from other sources are required to submit appropriate evidence, including budget information related to the other sources, to demonstrate that there is no direct overlap in funding.

Proposals utilising Gilead or Kite product(s) are not eligible for funding through the Research Scholars Program. Proposals involving Gilead or Kite product(s) should be submitted for review under the Investigator-Sponsored Research Grant Program through the ISR online portal.

Proposals are reviewed by an independent Scientific Review Committee, (no Commercial involvement in review or selection, i.e., Marketing, Sales, and Commercial Strategy), and are reviewed based upon the criteria outlined on this website.

While the Research Scholars Program is intended to support independent research by emerging investigators that is unrelated to Gilead’s and Kite’s strategies, all research projects selected by the Scientific Review Committee will need to be approved by an internal validation committee that may, in rare circumstances, be unable to support research if it directly compromises the existing Gilead and/or Kite Oncology portfolio of evidence.

• GILEAD and the GILEAD logo are registered
• trademarks of Gilead Sciences, Inc., or one of its related companies. Kite
• and the Kite Logo are registered trademarks of Kite, a Gilead company.
• © 2022 Gilead Sciences, Inc. All rights reserved.

• November 2022, IHQ-UNB-2912